Dr. Tram Tran, Chief Medical Officer of Glympse Bio, is developing biosensor technology that is able to measure protease activity from a blood sample to detect and monitor disease. Here she discusses recently published data demonstrating that Glympse’s platform can be applied for the sensitive detection of hepatocellular carcinoma or HCC, the most common form of liver cancer. This marks the first demonstration of the platform outside of NASH, the lead indication for the diagnostic technology.
Tram Tran is a renowned liver and viral specialist who brings over 20 years of academic and industry experience as a physician scientist to Glympse. She previously worked at Gilead Sciences as the Vice President of Medical Affairs, Global Head, Liver Diseases (HBV, HCV, HDV), Fibrosis (NASH, PSC) and COVID-19. Prior to her work at Gilead, Dr. Tran was the Medical Director of Liver Transplantation, GI Fellowship Program Director at Cedars-Sinai Medical Center, and a Professor of Medicine at the Geffen School of Medicine at the University of California, Los Angeles (UCLA). She has authored and co-authored over 150 abstracts, published manuscripts and book chapters, and has been extensively involved in clinical trials and National Institutes of Health (NIH) funded research. Dr. Tran earned her undergraduate degree at UCLA, received her M.D. from New York Medical College, continued her training in internal medicine at Cedars Sinai Medical Center, and completed Gastroenterology and Transplant Hepatology fellowships at UCLA, where she maintains clinical and teaching activities.